These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 17351376)

  • 1. Reduced levels of N-terminal-proatrial natriuretic peptide in hypertensive patients with metabolic syndrome and their relationship with left ventricular mass.
    Rubattu S; Sciarretta S; Ciavarella GM; Venturelli V; De Paolis P; Tocci G; De Biase L; Ferrucci A; Volpe M
    J Hypertens; 2007 Apr; 25(4):833-9. PubMed ID: 17351376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Markers of inflammation and fibrosis are related to cardiovascular damage in hypertensive patients with metabolic syndrome.
    Sciarretta S; Ferrucci A; Ciavarella GM; De Paolis P; Venturelli V; Tocci G; De Biase L; Rubattu S; Volpe M
    Am J Hypertens; 2007 Jul; 20(7):784-91. PubMed ID: 17586414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natriuretic peptides in patients with aortic stenosis.
    Qi W; Mathisen P; Kjekshus J; Simonsen S; Bjørnerheim R; Endresen K; Hall C
    Am Heart J; 2001 Oct; 142(4):725-32. PubMed ID: 11579366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-terminal pro-atrial natriuretic peptide reflects cardiac remodelling in stage 1 hypertension.
    Partanen N; Husso M; Vuolteenaho O; Sipola P; Ruskoaho H; Peuhkurinen K; Magga J
    J Hum Hypertens; 2011 Dec; 25(12):746-51. PubMed ID: 21248782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain natriuretic peptide as a marker for hypertensive left ventricular hypertrophy: changes during 1-year antihypertensive therapy with angiotensin-converting enzyme inhibitor.
    Kohno M; Horio T; Yokokawa K; Yasunari K; Ikeda M; Minami M; Kurihara N; Takeda T
    Am J Med; 1995 Mar; 98(3):257-65. PubMed ID: 7872342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-type natriuretic peptide and left ventricular hypertrophy in hypertensive patients.
    Almeida P; Azevedo A; Rodrigues R; Dias P; Friões F; Vazquez B; Abreu-Lima C; Bettencourt P; Barros H
    Rev Port Cardiol; 2003 Mar; 22(3):327-36. PubMed ID: 12847875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of N-terminal proatrial natriuretic peptide plasma levels in a survey of adult male population from Southern Italy.
    Rubattu S; Barbato A; Marchitti S; Iacone R; Di Castro S; Evangelista A; Stanzione R; Ippolito R; Sciarretta S; Palmieri L; Volpe M; Strazzullo P;
    J Hypertens; 2010 Aug; 28(8):1638-45. PubMed ID: 20453667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving cardiovascular risk stratification in essential hypertensive patients by indexing left ventricular mass to height(2.7).
    Cuspidi C; Giudici V; Negri F; Meani S; Sala C; Zanchetti A; Mancia G
    J Hypertens; 2009 Dec; 27(12):2465-71. PubMed ID: 19898252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of metabolic syndrome on left ventricular mass in overweight and obese hypertensive subjects.
    Mulè G; Nardi E; Cottone S; Cusimano P; Incalcaterra F; Giandalia ME; Palermo A; Mezzatesta G; Cerasola G
    Int J Cardiol; 2007 Oct; 121(3):267-75. PubMed ID: 17258825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of plasma atrial natriuretic peptide, N-terminal proatrial natriuretic peptide, and brain natriuretic peptide levels with coronary artery stenosis in patients with normal left ventricular systolic function.
    Nishikimi T; Mori Y; Ishimura K; Tadokoro K; Yagi H; Yabe A; Horinaka S; Matsuoka H
    Am J Med; 2004 Apr; 116(8):517-23. PubMed ID: 15063812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obese and nonobese patients with essential hypertension show similar N-terminal proBNP plasma levels.
    Cortés R; Otero MR; Morillas P; Roselló-Lletí E; Grigorian L; Martínez-Dolz L; de Burgos FG; Calabuig JR; Soria F; Lozano T; Portolés M; Bertomeu V
    Am J Hypertens; 2008 Jul; 21(7):820-5. PubMed ID: 18443568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Atrial natriuretic peptide, left ventricular mass and renin-angiotensin-aldosterone system in essential arterial hypertension of a mild or moderate degree].
    Gambini G; Talamonti D; Valori C
    G Ital Cardiol; 1992 Dec; 22(12):1397-403. PubMed ID: 1294423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-terminal proatrial natriuretic peptide and prognosis in patients with heart failure and preserved systolic function.
    Andersson B; Hall C
    J Card Fail; 2000 Sep; 6(3):208-13. PubMed ID: 10997746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natriuretic peptides as markers of preclinical cardiac disease in obesity.
    Grandi AM; Laurita E; Selva E; Piantanida E; Imperiale D; Giovanella L; Guasti L; Venco A
    Eur J Clin Invest; 2004 May; 34(5):342-8. PubMed ID: 15147331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nt-proANP in plasma, a marker of salt sensitivity, is reduced in type 2 diabetes patients.
    Melander O; Frandsen E; Magnusson M; Grubb A; Jovinge S; Groop L
    J Intern Med; 2005 Mar; 257(3):281-8. PubMed ID: 15715685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relationship between serum leptin levels and left ventricular hypertrophy in obese hypertensive patients].
    Kartal O; Inal V; Baysan O; Sağlam K
    Anadolu Kardiyol Derg; 2008 Oct; 8(5):342-6. PubMed ID: 18849224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inappropriate left ventricular mass is associated with microalbuminuria independently of left ventricular hypertrophy in primary hypertension.
    Ratto E; Leoncini G; Viazzi F; Bezante GP; Falqui V; Parodi A; Conti N; Tomolillo C; Deferrari G; Pontremoli R
    J Hypertens; 2008 Feb; 26(2):345-50. PubMed ID: 18192849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease.
    Elmas E; Brueckmann M; Lang S; Kälsch T; Haghi D; Sueselbeck T; Dempfle CE; Borggrefe M
    Int J Cardiol; 2008 Aug; 128(2):244-9. PubMed ID: 17673312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Arrhythmia risk and noninvasive markers in hypertensive left ventricular hypertrophy].
    Akdeniz B; Güneri S; Badak O; Aslan O; Tamci B
    Anadolu Kardiyol Derg; 2002 Jun; 2(2):121-9; AXVII. PubMed ID: 12134537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.